Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05934903 · ClinicalTrials.gov registry record · NA
Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT05934903: Clinical Trial NA study, sponsored by Yale University.
NCT05934903 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05934903, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
Status epilepticus, or recurrent seizures without return to baseline, is a neurologic emergency. Refractory status epilepticus occurs when seizures are resistant to multiple first line anti-seizure medications. The ability to quickly stop seizures is paramount. Transcranial direct current simulation is a non-invasive, easily administered therapy that can potentially help reduce seizure burden. The goal of this feasibility study is to assess the ability of the study site to enroll patients admitted with refractory seizures or those with abnormal brain wave patterns to take part in a study looking to use transcranial direct current stimulation as an adjunctive treatment. The main questions it aims to answer are: * What is the recruitment capability of the study site? * How well can the study site adhere to study protocol? * Are there any adverse effects of using the transcranial direct current stimulation device? * How do patients' brain wave studies respond to the stimulation? Participants will be asked to consider joining the study. Once joined, researchers will randomly assign participants to compare transcranial stimulation versus sham stimulation to see if this will affect the participant's brain wave patterns.
Primary Outcome
Recruitment capability of the study site will be assessed as the incidence of patients admitted with RSE/SRSE or IIC burden \> 50% within a 24 month period. Participants admitted undergoing cEEG monitoring will be screened for having RSE or IIC burden \>50% on a weekly basis.
Interventions
- DEVICE Transcranial Direct Current Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2025-03-31 |
| Phase | NA |
Why NCT05934903 stopped before completion
NCT05934903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Transcranial Direct Current Stimulation is the first listed.
NCT05934903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05934903 about?
NCT05934903 is a clinical study titled "Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus". Status epilepticus, or recurrent seizures without return to baseline, is a neurologic emergency. Refractory status epilepticus occurs when seizures are resistant to multiple first line anti-seizure medications. The ability to quickly stop seizures is paramount. Transcranial direct current simulation...
What is the current status of trial NCT05934903?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2023-08-31. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT05934903?
The interventions under investigation include: Transcranial Direct Current Stimulation (DEVICE).
Who is sponsoring clinical trial NCT05934903?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05934903's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI